In both of these studies, CagriSema was well-tolerated with an acceptable safety profile, with similar results reported in a phase 1b study in participants with overweight or obesity [7] and a phase 2 study in participants with type 2 diabetes [4]
Peptide potential: BPC-157 supporting tissue repair and vascular regeneration post-surgery
Petersen JA, Wilm BJ, von Meyenburg J, Schubert M, Seifert B, Najafi Y, et al
This results in changes to the work RVU pool, and therefore, yields a different estimated conversion factor
Results: With regular injections (typically once a week or as recommended), clients often report improved energy levels, better fat loss results, and an overall sense of well-being